CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR

NCT07210242 ·Status: NOT_YET_RECRUITING

The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT

NCT06558253 ·Status: RECRUITING ·Phase: PHASE1

Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010

NCT03111745 ·Status: COMPLETED

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

NCT00716911 ·Status: COMPLETED ·Phase: NA

Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

NCT06525519 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

NCT06334367 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure

NCT01481649 ·Status: COMPLETED

Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation

NCT02659657 ·Status: UNKNOWN ·Phase: PHASE2

Optimal Timing of Hepatitis B Vaccination After Transplants

NCT06888479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

NCT06294691 ·Status: RECRUITING ·Phase: PHASE3

Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation

NCT07181330 ·Status: COMPLETED

Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

NCT03101423 ·Status: UNKNOWN ·Phase: NA

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355 ·Status: RECRUITING

The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes

NCT07113730 ·Status: NOT_YET_RECRUITING

Prophylactic Application of Donor-derived TCM After Allogeneic HSCT

NCT02758223 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

NCT06208137 ·Status: RECRUITING ·Phase: NA

Role of aGVHD Biomarkers on aGVHD Risks

NCT04284904 ·Status: COMPLETED

Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

NCT05923814 ·Status: UNKNOWN ·Phase: PHASE2

Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

NCT06657391 ·Status: RECRUITING ·Phase: PHASE2

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

NCT06362967 ·Status: RECRUITING ·Phase: PHASE2

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies

NCT06294678 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT

NCT04412811 ·Status: COMPLETED

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

NCT00898612 ·Status: WITHDRAWN

Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCT

NCT05075837 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

NCT06000306 ·Status: COMPLETED